Invatec inks distribution deal with Lumen
Invatec, a provider of interventional products, has entered a global distribution agreement with Lumen Biomedical to distribute the FiberNet Embolic Protection System (EPS), which is indicated for the treatment of patients receiving endovascular intervention for carotid artery disease.
The product, which received FDA clearance in November 2008, also has CE Mark approval for use during carotid and saphenous vein graft procedures.
The FiberNet system features a 3D design composed of a matrix of fibers which allows for the entrapment of smaller particles, according to the Bethlehem, Pa.-based Invatec and the Plymouth, Minn.-based Lumen.
The low-profile filter is mounted on a guidewire, needing no delivery system to cross the lesion. The FiberNet EPS will treat vessels ranging from 3.5 to 7 mm and its design ensures wall apposition, according to the firms. After the particles have been captured, the FiberNet filter is retrieved into the retrieval catheter under aspiration and removed from the patient.
The product, which received FDA clearance in November 2008, also has CE Mark approval for use during carotid and saphenous vein graft procedures.
The FiberNet system features a 3D design composed of a matrix of fibers which allows for the entrapment of smaller particles, according to the Bethlehem, Pa.-based Invatec and the Plymouth, Minn.-based Lumen.
The low-profile filter is mounted on a guidewire, needing no delivery system to cross the lesion. The FiberNet EPS will treat vessels ranging from 3.5 to 7 mm and its design ensures wall apposition, according to the firms. After the particles have been captured, the FiberNet filter is retrieved into the retrieval catheter under aspiration and removed from the patient.